A few genetic polymorphisms of TP53 are known to have a significant effect on cancer susceptibility. Intron 3 16 bp duplication polymorphism of TP53 has been reported to be associated with breast cancer, colorectal cancer, lung cancer and other cancers, but the reported results remain inconclusive. The present study, a meta-analysis including a total of 9801 cases and 10 391 controls from 26 studies, revealed that the 16 bp insertion (Ins) allele is significantly associated with an increased cancer risk in overall analysis [Ins/Ins 1 deletion (Del)/Ins versus Del/Del: odds ratio (OR) 5 1.14, 95% confidence interval (CI) 5 1.02-1.27, P 5 0.02; Ins/Ins versus Del/Del: OR 5 1.35, 95% CI 5 1.11-1.63, P 5 0.002; Del/Ins versus Del/Del: OR 5 1.10, 95% CI 5 0.98-1.23, P 5 0.11.), particularly in breast cancer subgroup (Ins/Ins 1 Del/Ins versus Del/Del: OR 5 1.16, 95% CI 5 1.03-1.31, P 5 0.02; Ins/Ins versus Del/Del: OR 5 1.81, 95% CI 5 1.30-2.52, P < 0.001; Del/Ins versus Del/Del: OR 5 1.10, 95% CI 5 0.97-1.25, P 5 0.13). The relative risks to the colorectal and lung cancers increased but their association power was relatively weak, which may result from a limited number of studies of these two cancer types. These results suggest that intron 3 16 bp duplication polymorphism of TP53 is potentially an important and clinically relevant genetic marker contributing to cancer susceptibility.
Introduction
The tumor suppressor gene TP53 plays a crucial role in regulating cell cycle arrest, apoptosis, DNA repair, cell growth and suppressing tumorigenesis (1, 2) . A few genetic polymorphisms in TP53 locus have been widely investigated in population studies for their association with cancer susceptibility (3) (4) (5) . For instance, codon 72 Arg . Pro polymorphism (rs1042522) has been most extensively characterized in association with cancer risk in both population and biological function studies (6) (7) (8) (9) (10) (11) .
It has been shown that of the 85 single-nucleotide polymorphisms compiled in the International Agency for Research on Cancer TP53 Mutation Database (http://www-p53.iarc.fr/PolymorphismView.asp), .80% occur in the non-coding sequences and most are presumed to have no cancer-related biological consequences. As a type of deletion (Del)/insertion (Ins) polymorphism, the intron 3 16 bp duplication polymorphism of TP53 (-/5#ACCTGGAGGGCTGGGG3#, TP53PIN3, rs17878362) (12) is a well-characterized one and has been extensively investigated in population-based association studies with cancer susceptibility. But the results remain inconsistent rather than conclusive. Some studies have correlated the intron 3 16 bp Ins allele with an increased risk of various cancers, including breast cancer (13) (14) (15) , colorectal cancer (16, 17) and lung cancer (18) . However, other groups have failed to confirm these results in population studies. Conversely, the 16 bp duplication polymorphism found a decreased risk of the case-control-studied cancers (19) (20) (21) (22) . In functional studies, Gemignani et al. (16) found that the 16 bp Ins allele was associated with lower level of TP53 transcript in lymphoblastoid cell lines, suggesting that this polymorphism causes an alteration in messenger RNA (mRNA) processing, which provides a possible molecular basis for the associated increase in risk of developing cancer. However, study of Woelfelschneider et al. (23) could not correlate the TP53PIN3 genotypes with TP53 mRNA expression levels in primary blood lymphocytes of prostate cancer patients.
In order to systematically study the association of the intron 3 duplication polymorphism of TP53 with cancer risk, a meta-analysis including a total of 9801 cases and 10 391 controls from 26 case-control studies was performed, aiming to provide the most comprehensive evidence for this variant and its association with cancer susceptibility.
Materials and methods
Literature search and data extraction Prospective cohort and cancer case-control studies of intron 3 16 bp duplication polymorphism of TP53 published from September 1995 to March 2009 were identified through computer-based searches of PubMed, Excerpta Medica Database and Web of Science by using search terms of 'TP53', 'p53', 'TP53PIN3', 'cancer', 'polymorphism' as well as their combinations. Selection criteria of an eligible study were (i) a case-control study evaluating intron 3 16 bp duplication polymorphism of TP53 and cancer risk; (ii) the diagnosis of cancer patients was confirmed pathologically and controls were confirmed as free from cancer and (iii) published in English language.
The data, including first author, published year, cancer type, original country, ethnicity of the sample, sample size, numbers of cases and controls with the Del/Del, Del/Ins and Ins/Ins genotypes, source of controls and genotyping method, were independently extracted by two investigators (Z.H. and X.L) and reached conformity on all items through consultation. Study of Perfumo et al. (17) that included different two case-control groups was considered as two independent studies Perfumo a and Perfumo b.
Statistical analysis
Crude odds ratios (ORs) together with their corresponding 95% confidence intervals (95% CIs) were used to calculate and assess the strength of association between intron 3 16 bp duplication polymorphism of TP53 and cancer risk.
The pooled ORs were performed for the models of Ins/Ins þ Del/Ins versus Del/Del, Ins/Ins versus Del/Del and Del/Ins versus Del/Del. Minor allele frequency in controls of the variant was calculated. The departure of frequencies from expected under Hardy-Weinberg equilibrium was assessed by chi-square goodness of fit tests in controls. Further analyses were done by subgrouping studies into breast, colorectal or lung cancer based on their cancer types and general population-or hospital-based source of controls.
For the heterogeneity test, a random-effect model (the DerSimonian and Laird method) (24) was used when P , 0.05, otherwise a fixed-effect model (the Mantel-Haenszel method) (25) was used. In random-effect model, we incorporated the random variation within the studies and the variation among the different studies, and in fixed-effect model, we assumed that all studies come from a common population and the effect size is not significantly different among the different studies.
Publication bias was tested graphically by using funnels plots, in which the standard error was plotted against the log(OR) to form a simple scatterplot, and the funnel plot asymmetry was assessed by the method of Egger's test. Asymmetric plots could indicate potential existing publication bias.
The statistical analyses were performed using StatsDirect statistical software (version 2.7.3, Liverpool, UK). All the P values were two sided. pooled analyses. Out of the 26 studies, nine focused on breast cancer, five on colorectal cancer, four on lung cancer, two on endometrial cancer and one, respectively, on bladder, ovarian, gastric, oral, cervical and head and neck cancer. The ethnicities studied were Caucasian, Asian or other mixed population. Table II ). The forest plots of the meta-analysis were presented as Figures 1 and 2 and supplementary Figures 1-4 (available at Carcinogenesis Online).
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Publication bias
The results of the funnel plots did not reveal any evidence of obvious asymmetry (shown in Figure 3 ). The shapes of the funnel plots 
Discussion
Genetic variants of TP53 have been well recognized in the etiology of several cancers (3) (4) (5) . The intron 3 duplication is the most wellcharacterized intronic TP53 polymorphism, but the reported associations with cancer risk among studies are inconsistent. Our present meta-analysis incorporating 26 case-control studies (9801 cases and Polymorphism of TP53 contributes to cancer susceptibility 10 391 controls) suggests that the intron 3 duplication is significantly associated with increased cancer risk, especially with increased breast cancer risk. How a duplication of intron 3 could increase the risk of developing cancer is yet to be established, but the 16 bp Ins to intron 3 of TP53 might influence alternative splicing of p53 protein, leading to unstable transcripts or proteins with altered activities. Gemignani et al. (16) reported a reduced amount of TP53 transcripts for this allele in immortalized lymphoblastoid cell lines relative to wild-type. These results were recapitulated with mRNA extracted directly from patient lymphocytes, providing a possible molecular basis for the associated increase in risk of developing cancer. However, because of strong linkage disequilibrium between the intron 3 duplication and the well-studied codon 72 variant, it has not been determined from these experiments whether the intron 3 duplication alone influences mRNA stability or if this effect requires the Pro codon 72 variant. Other investigators have reported that a TP53 haplotype (codon 72 Arg/Pro, intron 6 G . A and intron 3 duplication) is associated with decreased apoptotic and DNA repair capacity in lymphoblastoid cell lines (18) . These experimental data suggest that the TP53 polymorphisms may affect p53 function.
The association of the TP53 intron 3 variant with increased risk of cancer in this meta-analysis was significant in overall and breast cancer subgroup but not in colorectal and lung cancer subgroups, which may result from the limited number of studies in the latter two subgroups. The risk association of this polymorphism with the source of controls was also analyzed, and both general populationand hospital-based subgroups showed an increased cancer risk. Metaanalysis is often dominated by a few large studies, which markedly reduces the evidence from smaller studies. We therefore calculated the overall pooled ORs on intron 3 duplication without the three largest studies (29, 31, 32) and found that results were consistent with an association with increased cancer risk.
Additionally, studies have reported significant differences of the 16 bp Ins allele frequency among different populations (18, 41) , which implies the potential utility of this marker in identifying differential cancer risk in diverse populations. This allele may also contribute to the phenotypic diversity with cancer risk, such as non-steroidal antiinflammatory drug use or age at first diagnosis (22, 42) , although these have to be further confirmed by large population studies.
Taken together, our results suggest that the intron 3 16 bp duplication polymorphism of TP53 is probably to be a potentially clinically significant genetic marker contributing to cancer susceptibility. Whether it could be applied to genotyping for clinical assessment requires large-scale population studies among different ethnicities and regions. 
